Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Alterity Therapeutics ( (AU:ATH) ) has shared an update.
Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, highlighting the completion of Phase 2 clinical trials for its lead asset, ATH434, in treating Multiple System Atrophy. The trials demonstrated a meaningful reduction in disease progression, earning FDA Fast Track and Orphan Drug Status, indicating strong commercial potential and hope for patients. The company is poised for late-stage clinical and commercial growth, with leadership transitions marking a new chapter in its journey.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company is known for its lead asset, ATH434, which has shown efficacy in clinical trials for Multiple System Atrophy (MSA), a rare Parkinsonian disorder. Alterity operates from Melbourne, Australia, and San Francisco, USA, and has a robust drug discovery platform for neurological diseases.
Average Trading Volume: 14,942,225
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
For an in-depth examination of ATH stock, go to TipRanks’ Overview page.